287 related articles for article (PubMed ID: 25205227)
1. Preclinical development of AMG 139, a human antibody specifically targeting IL-23.
Köck K; Pan WJ; Gow JM; Horner MJ; Gibbs JP; Colbert A; Goletz TJ; Newhall KJ; Rees WA; Sun Y; Zhang Y; O'Neill JC; Umble-Romero AN; Prokop SP; Krill CD; Som L; Buntich SA; Trimble MW; Tsuji WH; Towne JE
Br J Pharmacol; 2015 Jan; 172(1):159-72. PubMed ID: 25205227
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.
Pan WJ; Hsu H; Rees WA; Lear SP; Lee F; Foltz IN; Rathanaswami P; Manchulenko K; Chan BM; Zhang M; Xia XZ; Patel SK; Prince PJ; Doherty DR; Sheckler CM; Reynhardt KO; Krill CD; Harder BJ; Wisler JA; Brandvig JL; Lynch JL; Anderson AA; Wienkers LC; Borie DC
Br J Pharmacol; 2013 May; 169(1):51-68. PubMed ID: 23425116
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
Kakkar T; Ma M; Zhuang Y; Patton A; Hu Z; Mounho B
Pharm Res; 2007 Oct; 24(10):1910-8. PubMed ID: 17520181
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.
Pan WJ; Köck K; Rees WA; Sullivan BA; Evangelista CM; Yen M; Andrews JM; Radford-Smith GL; Prince PJ; Reynhardt KO; Doherty DR; Patel SK; Krill CD; Zhou K; Shen J; Smith LE; Gow JM; Lee J; Treacy AM; Yu Z; Platt VM; Borie DC
Br J Clin Pharmacol; 2014 Dec; 78(6):1315-33. PubMed ID: 24803302
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
[TBL] [Abstract][Full Text] [Related]
6. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
8. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Nnane IP; Xu Z; Zhou H; Davis HM
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Hart TK; Blackburn MN; Brigham-Burke M; Dede K; Al-Mahdi N; Zia-Amirhosseini P; Cook RM
Clin Exp Immunol; 2002 Oct; 130(1):93-100. PubMed ID: 12296858
[TBL] [Abstract][Full Text] [Related]
10. Prediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases.
Li H; Köck K; Wisler JA; Rees WA; Prince PJ; Reynhardt KO; Hsu H; Yu Z; Borie DC; Salinger DH; Pan WJ
Pharmacol Res Perspect; 2015 Feb; 3(1):e00098. PubMed ID: 25692016
[TBL] [Abstract][Full Text] [Related]
11. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody.
Enright BP; Tornesi B; Weinbauer GF; Blaich G
Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752
[TBL] [Abstract][Full Text] [Related]
12. Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein.
Kroenke MA; Starcevic Manning M; Zuch de Zafra CL; Zhang X; Cook KD; Archer M; Lolkema MP; Wang J; Hoofring S; Saini G; Aeffner F; Ahern E; Cabanas EG; Govindan R; Hui M; Gupta S; Mytych DT
Front Immunol; 2024; 15():1345473. PubMed ID: 38343535
[TBL] [Abstract][Full Text] [Related]
13. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
14. An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody.
Breslin WJ; Hilbish KG; Martin JA; Halstead CA; Newcomb DL; Chellman GJ
Birth Defects Res B Dev Reprod Toxicol; 2015 Jun; 104(3):100-16. PubMed ID: 26195230
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and translational pharmacology of afucosylated anti-CCR8 antibody for depletion of tumour-infiltrating regulatory T cells.
Gampa G; Spinosa P; Getz J; Zhong Y; Halpern W; Esen E; Davies J; Chou C; Kwong M; Wang Y; Arenzana TL; Shivva V; Huseni M; Hsieh R; Schartner J; Koerber JT; Rutz S; Hosseini I
Br J Pharmacol; 2024 Jul; 181(13):2033-2052. PubMed ID: 38486310
[TBL] [Abstract][Full Text] [Related]
17. Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey.
Katagiri R; Ishihara-Hattori K; Frings W; Amano J; Fuchs A; Chiba S
Birth Defects Res; 2017 Jul; 109(11):843-856. PubMed ID: 28504465
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.
Burgess TL; Sun J; Meyer S; Tsuruda TS; Sun J; Elliott G; Chen Q; Haniu M; Barron WF; Juan T; Zhang K; Coxon A; Kendall RL
Mol Cancer Ther; 2010 Feb; 9(2):400-9. PubMed ID: 20124448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
